NewAmsterdam Pharma Company N.V.
Símbolo: NAMS
NASDAQ
21.86
USDPrecio de mercado actual
87.5675
Ratio PER
0.0000
Ratio PEG
1.95B
Capitalización MRK
- 0.00%
Rendimiento DIV
NewAmsterdam Pharma Company N.V. (NAMS) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 340.4 | 438.5 | 53.1 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 1.9 | 1.9 | 4.3 | ||||
balance-sheet.row.inventory | 0 | -1.9 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 6.3 | 7.6 | 1.5 | ||||
balance-sheet.row.total-current-assets | 0 | 346.8 | 448.1 | 58.9 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0.2 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0.2 | 82.9 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.2 | 83.2 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0.1 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0.3 | 83.5 | 0.9 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.account-payables | 0 | 16.9 | 11.1 | 6.2 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 2.8 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0.1 | ||||
Deferred Revenue Non Current | 0 | 1 | 4.5 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 24 | 11.3 | 0 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 8.8 | 11.6 | 0.1 | ||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.total-liab | 0 | 58.7 | 47.1 | 10 | ||||
balance-sheet.row.preferred-stock | 0 | 317 | 0 | 0 | ||||
balance-sheet.row.common-stock | 0 | 10.2 | 599.2 | 83.9 | ||||
balance-sheet.row.retained-earnings | 0 | -317 | -119.4 | -34.7 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 4.4 | 4.7 | 0.6 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 273.8 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.net-debt | 0 | -340.4 | -438.4 | -52.9 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -176.9 | -78.1 | -28.6 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.1 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 5.2 | 0 | -1.4 | ||||
cash-flows.row.stock-based-compensation | 0 | 24.6 | 3.9 | 1 | ||||
cash-flows.row.change-in-working-capital | 0 | 5.9 | 11.5 | 3.8 | ||||
cash-flows.row.account-receivables | 0 | 3.7 | -3.9 | -4.6 | ||||
cash-flows.row.inventory | 0 | -3.7 | 5.9 | -0.1 | ||||
cash-flows.row.account-payables | 0 | 5.1 | -2 | 8.6 | ||||
cash-flows.row.other-working-capital | 0 | 0.8 | 11.5 | 0 | ||||
cash-flows.row.other-non-cash-items | 0 | 0 | 70.6 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 8.1 | 377.8 | 69 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.8 | -2.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 8.9 | 375.2 | 69 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5.1 | 1.6 | 1.4 | ||||
cash-flows.row.net-change-in-cash | 0 | -127.3 | 385.4 | 45.2 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 340.4 | 438.5 | 53.1 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 467.7 | 53.1 | 7.9 | ||||
cash-flows.row.operating-cash-flow | 0 | -141.2 | 8 | -25.2 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -141.2 | 8 | -25.2 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 14.1 | 97.5 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 14 | 97.4 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.cost-and-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.interest-income | 0 | 11.3 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 60.7 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -183 | -67.6 | -29.8 | ||||
income-statement-row.row.income-before-tax | 0 | -176.9 | -78.1 | -28.6 | ||||
income-statement-row.row.income-tax-expense | 0 | 0 | 70.8 | 0.2 | ||||
income-statement-row.row.net-income | 0 | -176.9 | -148.9 | -28.8 |
Preguntas frecuentes
Cuánto es NewAmsterdam Pharma Company N.V. (NAMS) activos totales?
NewAmsterdam Pharma Company N.V. (NAMS) los activos totales son 347097000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son N/A.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 1.000.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -0.345.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.206.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -0.335.
¿Qué es NewAmsterdam Pharma Company N.V. (NAMS) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -176937000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 60000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 189195000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 0.000.